Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?Bristol-Myers’ (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.


Read More At Article Source | Article Attribution